Most common complication of diabetes; distal symmetric stocking-glove sensorimotor neuropathy.
Also known as: diabetic neuropathy, diabetic peripheral neuropathy, DPN, distal symmetric polyneuropathy, DSPN
Overview
Distal symmetric, length-dependent, predominantly sensory polyneuropathy that develops as a complication of long-standing diabetes mellitus, after exclusion of other causes. Encompasses several syndromes; distal symmetric polyneuropathy (DSPN) is the most common form.
Epidemiology
Prevalence ~30-50% of patients with diabetes (rises with disease duration); ~10-20% have painful diabetic neuropathy. The most common cause of peripheral neuropathy in the US. Leading cause of non-traumatic lower-extremity amputation.
Try two board-style Diabetic Peripheral Neuropathy questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1NeurologyEasy
A 60-year-old male with type 2 diabetes mellitus (T2DM) has right foot numbness, tingling, and burning pain that is worse at night. Sensation to monofilament is absent at the plantar surface of the great toe bilaterally. Nerve conduction studies show reduced sensory amplitudes and mildly slowed conduction velocities in bilateral lower extremities in a length-dependent pattern. Which of the following is the most likely diagnosis?
AAlcoholic polyneuropathy
BVitamin B12 deficiency neuropathy
CUremic polyneuropathy
DDiabetic peripheral neuropathy
EHypothyroid polyneuropathy
Reveal answer & full explanation
Correct answer: D — Diabetic peripheral neuropathy
AAlcoholic polyneuropathy
BVitamin B12 deficiency neuropathy
CUremic polyneuropathy
DDiabetic peripheral neuropathy✓
EHypothyroid polyneuropathy
Why Diabetic peripheral neuropathy is correct
Diabetic peripheral neuropathy (DPN) is the most common form of peripheral neuropathy worldwide.
Presents as a length-dependent polyneuropathy with stocking-glove distribution, starting in the feet and ascending symmetrically — matching this patient's bilateral plantar foot findings.
Nerve conduction studies (NCS) show reduced sensory amplitudes (axonal loss) with mildly slowed conduction velocities, as seen here.
Why the others are wrong
Vitamin B12 deficiency neuropathy — also causes length-dependent neuropathy but typically includes posterior column signs (loss of vibration and proprioception) and may show macrocytosis; T2DM on metformin is a risk factor, but NCS pattern and clinical context favor DPN here.
Hypothyroid polyneuropathy — hypothyroidism can produce a distal sensory polyneuropathy, but it is uncommon, is usually accompanied by cold intolerance, weight gain, constipation, and delayed relaxation of the ankle reflexes, and more often presents as an entrapment neuropathy such as carpal tunnel syndrome; none of those features is described here.
Uremic polyneuropathy — requires advanced kidney failure (stage 4-5 chronic kidney disease or dialysis) and typically produces a sensorimotor axonal neuropathy with prominent restless legs and cramps; no renal impairment is reported in this patient.
Alcoholic polyneuropathy — chronic heavy drinking causes a very similar painful, length-dependent, predominantly sensory axonal neuropathy with burning feet, so it is a real mimic, but it requires sustained heavy alcohol use, which is not described here; in a patient with T2DM and this classic distal symmetric pattern, DPN remains the most likely cause.
Neuropathic pain pharmacotherapy: duloxetine, pregabalin, gabapentin, or amitriptyline.
Topical capsaicin or lidocaine patches for localized pain.
Avoid chronic opioids for diabetic peripheral neuropathy.
Question 2NeurologyMedium
A 62-year-old man with diabetes has burning bilateral foot pain and decreased vibration sense. Which of the following best explains this condition?
AImmune-mediated peripheral nerve demyelination
BLumbosacral nerve root compression
CPeripheral arterial occlusive disease
DLength-dependent axonal peripheral nerve injury
EPosterior column degeneration from B12 deficiency
Reveal answer & full explanation
Correct answer: D — Length-dependent axonal peripheral nerve injury
AImmune-mediated peripheral nerve demyelination
BLumbosacral nerve root compression
CPeripheral arterial occlusive disease
DLength-dependent axonal peripheral nerve injury✓
EPosterior column degeneration from B12 deficiency
Why Length-dependent axonal peripheral nerve injury is correct
Diabetic peripheral neuropathy is a distal symmetric, length-dependent polyneuropathy.
Chronic hyperglycemia causes metabolic and microvascular damage that strikes the longest axons first, hence the feet.
Symmetric burning pain with reduced vibration in a stocking pattern is the classic signature.
Why the others are wrong
Lumbosacral nerve root compression — Radiculopathy causes asymmetric, dermatomal pain with focal weakness, not a symmetric stocking distribution (asymmetric-pattern trap).
Posterior column degeneration from B12 deficiency — B12 deficiency also impairs vibration but typically adds brisk reflexes and a positive Romberg, and is a separate cause to test for, not the default in diabetes (overlapping-sensory trap).
Peripheral arterial occlusive disease — PAD causes claudication, cool pulseless feet, and ischemic rest pain rather than a burning sensory neuropathy with preserved warmth (vascular-vs-neuropathic trap).
Immune-mediated peripheral nerve demyelination — CIDP, the classic chronic immune-mediated demyelinating neuropathy, also reduces vibration sense, but it typically causes symmetric proximal as well as distal weakness with reduced or absent reflexes in all limbs and markedly slowed nerve conduction, whereas diabetic neuropathy is primarily axonal and begins with distal burning pain and sensory loss in the feet (axonal-vs-demyelinating trap).
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Diabetic Peripheral Neuropathy outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Chronic kidney disease (uremic neuropathy) — Advanced renal failure; improves with dialysis or transplant
Monoclonal gammopathy / amyloidosis — SPEP/UPEP, immunofixation, free light chains; check in older patients with rapidly progressive or painful neuropathy
Vasculitis (mononeuritis multiplex) — Multifocal, asymmetric, often painful; constitutional symptoms; nerve biopsy if needed
Chronic inflammatory demyelinating polyneuropathy (CIDP) — Symmetric proximal AND distal weakness, areflexia, elevated CSF protein; treat with IVIG, steroids, plasma exchange — distinct from DPN and IMPORTANT not to miss
Hereditary neuropathy (Charcot-Marie-Tooth) — Family history, foot deformity (pes cavus, hammer toes), early onset
Heavy metal toxicity (lead, arsenic, mercury), HIV, hepatitis C, Lyme disease, paraneoplastic — History clues, targeted serology and toxicology
Diagnostic workup
Diagnostic criteria
ADA/Toronto Consensus: typical DPN = patient with diabetes and distal symmetric polyneuropathy attributable to diabetes after exclusion of other causes; supported by characteristic signs/symptoms and confirmed by nerve conduction studies (in atypical or research settings).
Labs
Confirm diabetes and assess control: fasting glucose, A1c
Exclude common alternative or coexisting causes: CBC, BMP, TSH, vitamin B12 (with MMA if borderline), serum/urine protein electrophoresis with immunofixation (especially in older patients or atypical features), LFTs
Consider HIV, hepatitis C, Lyme, heavy metals, paraneoplastic antibodies if clinical suspicion
Lipid panel (cardiovascular risk and triglyceride-related neuropathy)
Imaging
Electrodiagnostic studies (NCS/EMG): not routinely required for typical DPN, but indicated for atypical features (asymmetric, predominantly motor, rapidly progressive, proximal involvement, areflexia, family history) to distinguish from CIDP, hereditary, or compressive neuropathies
Screen for DPN starting at diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes, then at least annually: history plus pinprick or temperature (small fiber), 128-Hz tuning fork vibration (large fiber), and 10-g monofilament (ulcer risk) (ADA 2026)
Skin biopsy for intraepidermal nerve fiber density and corneal confocal microscopy — research/specialty tools for small-fiber neuropathy
Diagnostic algorithm
Drug Class
Examples
Common Adverse Effects
Notes
Gabapentinoid
Pregabalin, gabapentin
Sedation, dizziness, edema, weight gain
Pregabalin FDA-approved; renal dose adjustment
SNRI
Duloxetine, venlafaxine
Nausea, dry mouth, somnolence, BP rise
Duloxetine FDA-approved; caution with hepatic disease
TCA
Amitriptyline, nortriptyline
Anticholinergic, QT prolongation, orthostasis
Avoid in elderly and cardiac disease; nortriptyline better tolerated
Tapentadol ER FDA-approved, but ADA 2026 and AAN 2022 advise against opioids for DPN pain except in rare circumstances
Topical
Capsaicin 8% patch, lidocaine 5%
Local burning, erythema (capsaicin)
Capsaicin 8% FDA-approved; in-office application
Neuromodulation
10-kHz spinal cord stimulation
Procedural risks, lead migration
FDA-approved 2021 for refractory painful DPN
Pharmacologic and neuromodulatory options for painful diabetic peripheral neuropathy.
Treatment
First-line
Glycemic control — strongest evidence for delaying progression in type 1 (DCCT/EDIC); more modest effect in type 2 (UKPDS, ACCORD). Avoid hypoglycemia in autonomic neuropathy.
Cardiovascular risk factor management: BP control (<130/80), statin therapy, smoking cessation, weight loss
Foot care education: daily inspection, well-fitting footwear, no barefoot walking, podiatry care; annual comprehensive foot exam by clinician; offload pressure points
Symptomatic treatment of painful DPN — FDA-approved or first-line agents (ADA 2026, AAN 2022):
Switch to another first-line class (or add a capsaicin 8% patch) when the initial agent fails or is not tolerated (AAN 2022); opioids, including tramadol and tapentadol, should not be used for painful DPN except in rare circumstances (ADA 2026, AAN 2022) — tapentadol ER holds FDA approval for DPN pain but is not guideline-endorsed (dependence, overdose risk)
Always exclude other causes of neuropathy before attributing all symptoms to diabetes — B12 deficiency is the most common reversible coexisting cause (and is worsened by metformin).
Asymmetric, predominantly motor, or rapidly progressive neuropathy should raise concern for CIDP, vasculitis, or paraneoplastic causes — order NCS/EMG and additional workup; CIDP is treatable (IVIG, steroids).
Annual foot exam with 10-g monofilament + tuning fork is the highest-yield screening intervention to prevent amputation.
Glycemic control is most effective at preventing neuropathy progression in type 1 DM; effect is more modest in type 2.
Treatment-induced neuropathy of diabetes ('insulin neuritis') can occur with rapid A1c reduction — counsel patients before intensifying therapy.
Charcot foot may mimic cellulitis (red, warm, swollen, painless) — recognize and offload immediately; missed Charcot leads to amputation.
Cardiovascular autonomic neuropathy (resting tachycardia, blunted heart rate variability, orthostasis) is associated with increased mortality — consider beta-blocker cautiously.
Avoid combination of tramadol with SSRIs/SNRIs (serotonin syndrome) and watch for QT prolongation with TCAs and methadone.
Painful DPN responds to gabapentinoids, duloxetine, or TCAs — choose based on comorbidities (renal function, mood, cardiac status).
References
ADA 2017 Position Statement — Pop-Busui R et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:136-154.
AAN 2022 — Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update (Price et al., Neurology 2022)
Toronto Consensus — Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments (Tesfaye et al., Diabetes Care 2010)
DCCT/EDIC — Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy (DCCT Research Group, Ann Intern Med 1995)
ADA 2026 — American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S261-S276.
Practice Neurology questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.